Medical Marketing and Media - Abbott sues Watson over Synthroid talk
In a federal court suit filed on June 12, Abbott Laboratories is asking for temporary and permanent injunctions to order Watson Pharmaceuticals to stop “false advertising and deceptive trade practices” about Abbott’s Synthroid (levothyroxine). Abbott says that through presentations to physicians, direct mail, and news releases, Watson is saying that (1) Synthroid will be taken off the market this August; (2) by not filing an New Drug Application (NDA), Abbott failed to comply with FDA’s August 1997 levothyroxine notice; (3) Synthroid is not safe and effective as demonstrated by FDA’s denial of a petition seeking to have it classified as GRAS/E; and (4) the fact that Watson’s Unithroid has received an NDA approval shows that it is superior to Synthroid and other levothyroxine drugs that have not yet received an NDA approval.
Most Popular
5 Regular Mistakes In Public Speaking
13 Job Interview Mistakes To Avoid
10 Jobs That Pay $30 An Hour
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
Abbott says these Watson statements “are false and misleading, and harm patients, physicians, and Abbott.”
Copyright CPS Communications Aug 2001
Provided by ProQuest Information and Learning Company. All rights Reserved
